Publication Cover
Natural Product Research
Formerly Natural Product Letters
Volume 36, 2022 - Issue 2
249
Views
3
CrossRef citations to date
0
Altmetric
Research Articles

Soulieoside U, a new cycloartane triterpene glycoside from Actaea vaginata

, , , , , , , , , , & show all
Pages 560-565 | Received 17 May 2020, Accepted 23 Jun 2020, Published online: 09 Jul 2020
 

Abstract

One new cycloartane triterpene bisdesmoside, soulieoside U, was isolated from the rhizomes of Actaea vaginata. Its structure was elucidated by extensive analysis of the NMR and MS data. Soulieoside U was evaluated for cytotoxic activities against three human cancer cell lines.

Graphical Abstract

Disclosure statement

No potential conflict of interest was reported by the authors.

Correction Statement

This article has been republished with minor changes. These changes do not impact the academic content of the article.

Additional information

Funding

This work was financially supported from the biodiversity survey and assessment project of the Ministry of Ecology and Environment of China [2019HJ2096001006], the CAMS Innovation Fund for Medical Sciences [CIFS, No. 2019-I2M-1-005], the National Major Scientific and Technological Special Project for “Significant New Drugs Development” [No.2015ZX09501005], the Foundation of Hunan Double First-rate Discipline Construction Projects of Bioengineering [YYZW2019-36], the Opening Project of Zhejiang Provincial Top Key Discipline of Pharmaceutical Sciences [YKFJ3-012] and the State Scholarship Fund from China Scholarship Council

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.